Octreotide Acetate Injection Small Volume Parenteral 0.1 mg

Octreotide Acetate Injection Small Volume Parenteral 0.1 mg 

Product : Octreotide Acetate Injection

Specification : 0.1mg

Standard : In - house

Packing : 5vials/box

Description :

Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin

Indications and Dosages :

➤➤To control symptoms associated with vasoactive intestinal peptide tumors (watery diarrhea) and metastatic carcinoid tumors (diarrhea and flushing)

i.m. injection

Adults currently receiving subcutaneous injections. 20 mg every 4 wk for 2 mo, with subcutaneous doses continued for 2 to 4 wk after I.M. injections start. If patient has positive response to initial 2-mo regimen, dosage reduced to 10 mg every 4 wk. If symptoms persist or increase after initial 2-mo regimen, dosage increased to 30 mg every 4 wk, as prescribed.

subcutaneous injection

Adults. Initial: 200 to 300 mcg daily in divided doses twice daily to four times a day, for first 2 wk. Maintenance: Individualized. Maximum: 450 mcg daily.

➤➤To treat symptoms of acromegaly, to suppress the release of growth hormone from pituitary tumors

i.v. or subcutaneous injection

Adults. Initial: 50 mcg three times a day Usual: 100 mcg three times a day Maximum: 1,500 mcg daily.

i.m. injection

Adults currently receiving subcutaneous injections. 20 mg every 4 wk for 3 mo; then adjusted as prescribed in response to serum growth hormone level. Maximum: 40 mg every 4 wk.

Route        Onset         Peak        Duration

SubQ        Unknown    Unknown    Up to 12 hr

Pharmacodynamics :

Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly.

Mechanism of action :

Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.